Stock declined on Thursday despite beating adjusted earnings estimates. The company missed on net revenue expectations ($938M vs. $948M consensus), and the analyst noted that results and near-term potential 'aren't impressive enough' to warrant ownership. While the company showed resilience in the chemical downcycle through pricing strategies, the mixed results and modest guidance did not inspire investor confidence.
While H. B. Fuller beat both revenue and EPS estimates in Q3 2026, the stock has significantly underperformed the broader market, declining 10.4% over the past month versus the S&P 500's 1.3% gain. The company received a Zacks Rank #4 (Sell) rating, indicating expected underperformance in the near term, which outweighs the positive earnings surprise.
Despite beating earnings estimates (+4.83% surprise) and revenue expectations, the stock has significantly underperformed the market (down 14.1% YTD vs S&P 500 up 13.4%). The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, indicating expected near-term underperformance.
While earnings growth is expected (15.9% EPS increase YoY), the recent 1.9% downward revision to consensus estimates and significant stock underperformance (-14.8% over past month) suggest investor caution. The Hold rating and mixed signals from estimate revisions warrant a neutral stance ahead of earnings.
Articles that tag FUL but are mainly about other companies.
Highlighted as a major player in North America with specific product innovations (Swift-melt PUR 400 series) for high-speed packaging applications, demonstrating strong market presence and technical advancement.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
